{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:10:56Z","timestamp":1790226656816,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Imatinib is the treatment of elderly or frail patients with chronic myeloid leukemia (CML). Trough levels of around 1000\u2009ng\/ml are considered as the target exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We searched for baseline parameters associated with imatinib pharmacokinetics, and studied the clinical impact of subsequent adaptive dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present data from 60 adult CML patients upon imatinib with therapeutic drug monitoring (TDM) and adaptive dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean trough levels after treatment initiation were 994.2\u2009\u00b1\u2009560.6\u00a0ng\/ml with 56% inter\u2010patient variability). Only 29% of patients were in the therapeutic range. Body weight, height, body surface area, body mass index (BMI), and age were associated with imatinib plasma levels on univariate analysis. Age and BMI remained the only parameters associated with imatinib trough levels on multivariate analysis. As severe toxicities have been previously reported in patients with low BMI treated with standard imatinib, we evaluated the extent to which low BMI may lead to plasma overexposure. We found a statistically significant difference in trough imatinib levels in patients with BMI\u2009&lt;\u200918.5\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , with exposure +61.5% higher than in patients with 18.5\u00a0&lt;\u2009BMI\u2009\u2264 \u200924.9 and +76.3% higher than in patients with BMI\u2009\u2265\u200925. After TDM with adaptive dosing, a statistically significant difference in dosing between patients was observed, with doses ranging from 200 to 700\u2009mg. No difference in toxicity or efficacy was observed regardless of BMI after adaptive dosing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data suggest that low BMI has a significant impact on imatinib exposure but that pharmacokinetically\u2010guided dosing limits its clinical impact in patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.13049","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:10:48Z","timestamp":1735877448000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Body mass index affects imatinib exposure: Real\u2010world evidence from TDM with adaptive dosing"],"prefix":"10.1111","volume":"39","author":[{"given":"Paul","family":"Maroselli","sequence":"first","affiliation":[{"name":"PRISM Biog\u00e9nop\u00f4le La Timone University Hospital of Marseille, APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Fanciullino","sequence":"additional","affiliation":[{"name":"COMPO Centre de Recherche en Canc\u00e9rologie de Marseille Inserm U1068  Marseille France"},{"name":"Pharmacy Unit La Conception University Hospital of Marseille APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Colle","sequence":"additional","affiliation":[{"name":"Hematology Dept La Conception University Hospital of Marseille APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Farnault","sequence":"additional","affiliation":[{"name":"Hematology Dept La Conception University Hospital of Marseille APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Roche","sequence":"additional","affiliation":[{"name":"Pharmacy Unit La Conception University Hospital of Marseille APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Venton","sequence":"additional","affiliation":[{"name":"Hematology Dept La Conception University Hospital of Marseille APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Costello","sequence":"additional","affiliation":[{"name":"Hematology Dept La Conception University Hospital of Marseille APHM  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-3410","authenticated-orcid":false,"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[{"name":"PRISM Biog\u00e9nop\u00f4le La Timone University Hospital of Marseille, APHM  Marseille France"},{"name":"COMPO Centre de Recherche en Canc\u00e9rologie de Marseille Inserm U1068  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200544090\u201000001"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318284ef11"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/11596990\u2010000000000\u201000000"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1082"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.03.023"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12007"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010116475"},{"key":"e_1_2_13_10_1","first-page":"35","article-title":"Population pharmacokinetics of imatinib mesylate in patients with chronic\u2010phase chronic myeloid leukaemia: results of a phase III study","volume":"60","author":"Schmidli H","journal-title":"Br J ClinPharmacol."},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02719.x"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081676"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2017.04.002"},{"key":"e_1_2_13_15_1","unstructured":"https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/topic-details\/GHO\/body-mass-indexLast Access 6th Nov 2024."},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201005\u20102596"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095\u2010016\u20102020\u20103"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010022\u201004454\u2010y"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2016.12.006"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061216"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1954"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.10.009"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23180"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000004"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.11.002"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010024\u201003675\u20109"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34725"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010024\u201005924\u20104"},{"key":"e_1_2_13_30_1","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-pragmatic-clinical-trials-preliminary-shared-experience-under-ctr-d-lacombe-eortc_en.pdfLast Access 6th Nov 2024."}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.13049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.13049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.13049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:18:04Z","timestamp":1773919084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.13049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/fcp.13049"],"URL":"https:\/\/doi.org\/10.1111\/fcp.13049","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"2024-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13049"}}